| Literature DB >> 29318108 |
Jaimie Mittal1, Wendy A Szymczak2, Noah Robbins1, Carol Harris3, Priya Nori1.
Abstract
We present a case of fatal community-acquired pneumonia (CAP) due to Acinetobacter baumannii, which is rarely reported in the northeastern United States. Previously reported cases originate from tropical and subtropical climates, and infection tends to have an aggressive course with a poor outcome. Appropriate antimicrobial therapy is crucial; however, the associated systemic inflammatory response may overwhelm host defenses, especially in patients with certain co-morbidities.Entities:
Keywords: Acinetobacter baumannii; Community-acquired; Pneumonia
Year: 2017 PMID: 29318108 PMCID: PMC5751873 DOI: 10.1016/j.idcr.2017.12.010
Source DB: PubMed Journal: IDCases ISSN: 2214-2509
Fig. 1Chest radiograph taken on admission at the outside hospital.
Susceptibilities of A. baumannii isolated in blood and respiratory cultures.
| Antibiotic Tested | Interpretation (MIC |
|---|---|
| Amikacin | Sensitive (<16) |
| Ampicillin/Sulbactam | Sensitive (<8/4) |
| Cefepime | Sensitive (<8) |
| Ceftazidime | Sensitive (4) |
| Ciprofloxacin | Sensitive (<1) |
| Gentamicin | Sensitive (<4) |
| Levofloxacin | Sensitive (<2) |
| Meropenem | Sensitive (<4) |
| Piperacillin | Sensitive (<16) |
| Tetracycline | Sensitive (<4) |
| Tobramycin | Sensitive (<4) |
| Trimethoprim-sulfamethoxazole | Sensitive (<2/38) |
Minimum inhibitory concentration.